How to Make the Diagnosis of ATTR Amyloidosis

Scripps Health

B. Sperry

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Scripps Health

M. Kittleson

Using Cardiac MRI to Assess Progression and Treatment Response

The France Foundation

D. Kwon

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

UCLA Health

D. Vucicevic

Cardiomyopathies: 2024 Wrap Up

Cardiology 2024 Year in Review

A. Masri

Patient Perspective: Cardiac Amyloidosis

Scripps Health

M. Nichols

Cardiac Amyloidosis: Transition from a Rare, Underdiagnosed and Untr…

The Texas Heart Institute

M. Maurer

Cardiac Amyloidosis: An Overlooked but Treatable Cause of HFpEF

Inova Heart and Vascular Institute - Advanced Heart Failure Symposium

SOHO 2022: Amyloidosis - Update and How To Use Novel Agents

SOHO 2022 Tenth Annual Meeting

S. Lentzsch

Emerging Therapies in Cardiac Amyloidosis

NYU Langone

M. Hanna

Interpreting a PYP Study for TTR Cardiac Amyloid

American Society of Nuclear Cardiology

P. Soman, M. Harinstein, S. Divakaran

Amyloidosis Types and Pathophysiology

Houston Methodist

B. Trachtenberg

CHEST 2023 Insights: Interstitial Lung Abnormality (ILA)

CHEST 2023 Insights

S. Raoof

ACC 2023: Practice-Changing Recommendations from the 2021 Chest Pain…

ACC 2023 Conference Coverage

R. Bullock-Palmer

Cardiac Amyloidosis: Evaluation and New Therapies

Cleveland Clinic Heart, Vascular and Thoracic Institute

M. Hanna

Therapies for Pulmonary Venous Hypertension: Updates on the Treatmen…

Scripps Health

R. Mohan

ACC 2022: Clinical Utility of Myocardial Blood Flow Assessment With …

ACC 2022 Conference Coverage

R. Thompson

Evaluation of Non-Ischemic Dilated Cardiomyopathy: Imaging and Genet…

Houston Methodist DeBakey Heart and Vascular Center

N. Fida

Glucagon Like Peptide 1 Receptor Agonists Use and Outcomes in Cardia…

Vikash Jaiwal

Lessons from the 2023 ACC Expert Consensus Decision Pathway on Compr…

Michelle Kittleson